A first Czech analysis of 1887 cases with monoclonal gammopathy
of undetermined significance

J 2017

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

SANDECKÁ, Viera, Roman HÁJEK, Luděk POUR, I. SPICKA, V. SCUDLA et. al.

Základní údaje

Originální název

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

Autoři

SANDECKÁ, Viera (703 Slovensko, garant), Roman HÁJEK (203 Česká republika, domácí), Luděk POUR (203 Česká republika), I. SPICKA (203 Česká republika), V. SCUDLA (203 Česká republika), E. GREGORA (203 Česká republika), J. RADOCHA (203 Česká republika), L. WALTEROVA (203 Česká republika), P. KESSLER (203 Česká republika), L. ZAHRADOVA (203 Česká republika), D. ADAMOVA (203 Česká republika), K. VALENTOVA (203 Česká republika), I. VONKE (203 Česká republika), J. OBERNAUEROVA (203 Česká republika), D. STAROSTKA (203 Česká republika), M. WROBEL (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Aneta MIKULÁŠOVÁ (203 Česká republika, domácí), L. RIHOVA (203 Česká republika), Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí), J. STRAUB (203 Česká republika), J. MINARIK (203 Česká republika), Zdeněk ADAM (203 Česká republika), Marta KREJČÍ (203 Česká republika), Zdeněk KRÁL (203 Česká republika) a V. MAISNAR (203 Česká republika)

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2017, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.595

Kód RIV

RIV/00216224:14110/17:00098729

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/ejh.12894

UT WoS

000403724300010

Klíčová slova anglicky

monoclonal gammopathy; multiple myeloma; progression; risk factors

Štítky

EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 3. 2018 16:41, Soňa Böhmová

Anotace

V originále

IntroductionMonoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. Patients and methodsWith the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-basedcohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. ResultsDuring the follow-up period (median 4years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration 1.5g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age 69years, and the level of serum hemoglobin at baseline <12.0g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. ConclusionThe new CMG model was established with an advantage for better identification of MGUS patients at low risk.

Citovat

SANDECKÁ, Viera, Roman HÁJEK, Luděk POUR, I. SPICKA, V. SCUDLA, E. GREGORA, J. RADOCHA, L. WALTEROVA, P. KESSLER, L. ZAHRADOVA, D. ADAMOVA, K. VALENTOVA, I. VONKE, J. OBERNAUEROVA, D. STAROSTKA, M. WROBEL, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Aneta MIKULÁŠOVÁ, L. RIHOVA, Sabina ŠEVČÍKOVÁ, J. STRAUB, J. MINARIK, Zdeněk ADAM, Marta KREJČÍ, Zdeněk KRÁL a V. MAISNAR. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2017, roč. 99, č. 1, s. 80-90. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12894.

@article{1398982,
   author = {Sandecká, Viera and Hájek, Roman and Pour, Luděk and Spicka, I. and Scudla, V. and Gregora, E. and Radocha, J. and Walterova, L. and Kessler, P. and Zahradova, L. and Adamova, D. and Valentova, K. and Vonke, I. and Obernauerova, J. and Starostka, D. and Wrobel, M. and Brožová, Lucie and Jarkovský, Jiří and Mikulášová, Aneta and Rihova, L. and Ševčíková, Sabina and Straub, J. and Minarik, J. and Adam, Zdeněk and Krejčí, Marta and Král, Zdeněk and Maisnar, V.},
   article_location = {Hoboken},
   article_number = {1},
   doi = {http://dx.doi.org/10.1111/ejh.12894},
   keywords = {monoclonal gammopathy; multiple myeloma; progression; risk factors},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance},
   volume = {99},
   year = {2017}
}

TY  - JOUR
ID  - 1398982
AU  - Sandecká, Viera - Hájek, Roman - Pour, Luděk - Spicka, I. - Scudla, V. - Gregora, E. - Radocha, J. - Walterova, L. - Kessler, P. - Zahradova, L. - Adamova, D. - Valentova, K. - Vonke, I. - Obernauerova, J. - Starostka, D. - Wrobel, M. - Brožová, Lucie - Jarkovský, Jiří - Mikulášová, Aneta - Rihova, L. - Ševčíková, Sabina - Straub, J. - Minarik, J. - Adam, Zdeněk - Krejčí, Marta - Král, Zdeněk - Maisnar, V.
PY  - 2017
TI  - A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance
JF  - European Journal of Haematology
VL  - 99
IS  - 1
SP  - 80-90
EP  - 80-90
PB  - Wiley-Blackwell
SN  - 09024441
KW  - monoclonal gammopathy
KW  - multiple myeloma
KW  - progression
KW  - risk factors
N2  - IntroductionMonoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. Patients and methodsWith the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-basedcohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. ResultsDuring the follow-up period (median 4years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration 1.5g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age 69years, and the level of serum hemoglobin at baseline <12.0g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. ConclusionThe new CMG model was established with an advantage for better identification of MGUS patients at low risk.
ER  -

SANDECKÁ, Viera, Roman HÁJEK, Luděk POUR, I. SPICKA, V. SCUDLA, E. GREGORA, J. RADOCHA, L. WALTEROVA, P. KESSLER, L. ZAHRADOVA, D. ADAMOVA, K. VALENTOVA, I. VONKE, J. OBERNAUEROVA, D. STAROSTKA, M. WROBEL, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Aneta MIKULÁŠOVÁ, L. RIHOVA, Sabina ŠEVČÍKOVÁ, J. STRAUB, J. MINARIK, Zdeněk ADAM, Marta KREJČÍ, Zdeněk KRÁL a V. MAISNAR. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2017, roč.~99, č.~1, s.~80-90. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12894.

Podrobný výpis o publikaci